Medindia

X

Cantel Medical Corp. to Present at the Needham & Company 12th Annual Growth Stock Conference

Tuesday, January 5, 2010 Press Release J E 4
Advertisement

LITTLE FALLS, N.J., Jan. 5 /PRNewswire-FirstCall/ -- CANTEL MEDICAL CORP. (NYSE: CMN) announced today that Andrew A. Krakauer, President & CEO, will be presenting at the Needham & Company, LLC 12th Annual Growth Stock Conference. The formal presentation is scheduled for 1:50 PM ET on Thursday, January 14, 2010 at The New York Palace Hotel, with a Q & A session immediately following the presentation. In addition, Mr. Krakauer and Seth R. Segel, Executive Vice President, will be available for separate one-on-one meetings during the day. The presentation will be available on the Investor Relations section of the Company's website: www.cantelmedical.com.

Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.  For more information, please visit http://www.cantelmedical.com.

SOURCE Cantel Medical Corp.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
americanVRS Provides Free Video Relay Services for...
S
Keryx Biopharmaceuticals Announces Special Protoco...